The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline is reported by Basch et al in the Journal of...
According to a study published in The Lancet Oncology, abiraterone acetate (Zytiga) taken in conjunction with prednisone significantly delays progression of pain and quality of life deterioration in men with metastatic castration-resistant prostate cancer. The study was led by Ethan Basch, MD,...